Analysis of antihypertensive regimens and their intended patients from three hospitals in Beijing

doi:10.5246/jcps.2013.04.054

Abstract

Abstract:

This study aimed to investigate various regimens of antihypertensive agents for different groups of patients and the outcomes in the real world. We retrospectively collected 974 prescriptions for hypertension from three hospitals in Beijing, along with medical records of 219 hypertensive patients from one of the hospitals to study the regimens and their effects on patients. The antihypertensive regimens were classified by different combinations of subclasses of antihypertensive agents. Nearly all prescriptions can be classified into 11 different antihypertensive regimens, and most of them are combination therapy. Grade III hypertension patients significantly (P<0.001) tend to be treated with regimens containing calcium channel blocker (CCB) and RAAS inhibitors, angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI). β-Blockers are more likely to be combined with CCB than with other categories of antihypertensive agents. Hydrochlorothiazide is less widely used than recommended.

Key words: Antihypertensive agents, Combination, Intended patients, Hypertension

CLC Number:

R969.4

Supporting:

Kai Zheng, Yingqi Sun, Yanhong Wei, Wei Yang, Weihua Kong, Hong Shao^*, Tiansheng Wang. Analysis of antihypertensive regimens and their intended patients from
three hospitals in Beijing[J]. , DOI: 10.5246/jcps.2013.04.054.

References

[1] Hu, D.Y.; Liu, L.S.; Yu, J.M.; Yao, C.H. Chin. J. Cardiol. 2010, 38, 230-238.
[2] Mancia, G.; Laurent, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Burnier, M.; Caulfield, M.J.; Cifkova, R.; Clement, D.; Coca, A.; Dominiczak, A.; Erdine, S.; Fagard, R.; Farsang, C.; Grassi, G.; Haller, H.; Heagerty, A.; Kjeldsen, S.E.; Kiowski, W.; Mallion, J.M.; Manolis, A.; Narkiewicz, K.; Nilsson, P.; Olsen, M.H.; Rahn, K.H.; Redon, J.; Rodicio, J.; Ruilope, L.; Schmieder, R.E.; Struijker-Boudier, H.A.; Van Zwieten, P.A.; Viigimaa, M.; Zanchetti, A. Blood Press. 2009, 18, 308-347.
[3] Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, A.M.; Kjeldsen, S.E.; Laurent, S.; Narkiewicz, K.; Ruilope, L.; Rynkiewicz, A.; Schmieder, R.E.; Boudier, H.A.; Zanchetti, A. J. Hypertens. 2007, 25, 1751-1762.
[4] Parati, G. J. Cardiovasc. Pharmacol. 2009, 53, 352-358.
[5] Chrysant, S.G. Am. J. Cardiovasc. Drugs. 2010, 10, 315-320.
[6] Mourad, J.J.; Le Jeune, S.; Pirollo, A.; Mourad, C.; Gaudouen, Y.; Lopez-Sublet, M. Curr. Med. Res. Opin. 2010, 26, 2263-2276.
[7] de la Sierra, A. J. Hum. Hypertens. 2009, 23, 503-511.
[8] Hasebe, N.; Kikuchi, K. J. Hypertens. 2005, 23, 445-453.
[9] Neutel, J.M.; Smith, D.H.G.; Weber, M.A.; Schofield, L.; Purkayastha, D.; Gatlin, M. J. Clin. Hypertens. 2005, 7, 641-646.
[10] Boutouyrie, P.; Achouba, A.; Trunet, P.; Laurent, S. Hypertension. 2010, 55, 1314-1322.
[11] Matsui, Y.; Eguchi, K.; O'Rourke, M.F.; Ishikawa, J.; Miyashita, H.; Shimada, K.; Kario, K. Hypertension. 2009, 54, 716-723.
[12] Jamerson, K.; Weber, M.A.; Bakris, G.L.; Dahlof, B.; Pitt, B.; Shi, V.; Hester, A.; Gupte, J.; Gatlin, M.; Velazquez, E.J. N. Engl. J. Med. 2008, 359, 2417-2428.
[13] Dahlof, B.; Sever, P.S.; Poulter, N.R.; Wedel, H.; Beevers, D.G.; Caulfield, M.; Collins, R.; Kjeldsen, S.E.; Kristinsson, A.; McInnes, G.T.; Mehlsen, J.; Nieminen, M.; O'Brien, E.; Ostergren, J. Lancet. 2005, 366, 895-906.
[14] Kjeldsen, S.E.; Weber, M.; Oparil, S.; Jamerson, K.A. Blood Press. 2008, 17, 260-269.
[15] Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, A.M.; Kjeldsen, S.E.; Laurent, S.; Narkiewicz, K.; Ruilope, L.; Rynkiewicz, A.; Schmieder, R.E.; Boudier, H.A.; Zanchetti, A.; Vahanian, A.; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L.; Erdine, S.; Kiowski, W.; Agabiti-Rosei, E.; Ambrosioni, E.; Lindholm, L.H.; Viigimaa, M.; Adamopoulos, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Bertomeu, V.; Clement, D.; Erdine, S.; Farsang, C.; Gaita, D.; Lip, G.; Mallion, J.M.; Manolis, A.J.; Nilsson, P.M.; O'Brien, E.; Ponikowski, P.; Redon, J.; Ruschitzka, F.; Tamargo, J.; van Zwieten, P.; Waeber, B.; Williams, B. J. Hypertens. 2007, 25, 1105-1187.
[16] Bisognano, J.D.; McLaughlin, T.; Roberts, C.S.; Tang, S.S. Vasc. Health Risk Manag. 2007, 3, 579-585.
[17] Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.J.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.J.; Roccella, E.J. Hypertension. 2003, 42, 1206-1252.
[18] Bartholow, M. Pharm. Times. 2010, 35-36. This article can be found online at http://www.pharmacytimes.com/publications/issue/2010/May2010/RxFocusTopDrugs-0510
[19] Garber, A.J.; Handelsman, Y.; Einhorn, D.; Bergman, D.A.; Bloomgarden, Z.T.; Fonseca, V.; Garvey, W.T.; Gavin III, J.R.; Grunberger, G.; Horton, E.S.; Jellinger, P.S.; Jones, K.L.; Lebovitz, H.; Levy, P.; McGuire, D.K.; Moghissi, E.S.; Nesto, R.W. Endocr. Pract. 2008, 14, 933-946.
[20] de Galan, B.E.; Perkovic, V.; Ninomiya, T.; Pillai, A.; Patel, A.; Cass, A.; Neal, B.; Poulter, N.; Harrap, S.; Mogensen, C.E.; Cooper, M.; Marre, M.; Williams, B.; Hamet, P.; Mancia, G.; Woodward, M.; Glasziou, P.; Grobbee, D.E.; MacMahon, S.; Chalmers, J. J. Am. Soc. Nephrol. 2009, 20, 883-892.
[21] Atkins, R.C.; Briganti, E.M.; Lewis, J.B.; Hunsicker, L.G.; Braden, G.; Champion, D.C.P.; DeFerrari, G.; Drury, P.; Locatelli, F.; Wiegmann, T.B.; Lewis, E.J. Am. J. Kidney Dis. 2005, 45, 281-287.
[22] Zhu, K.C.; Cao, G.Y.; Hu, X. J. Chin. Pharm. Sci. 2012, 21, 205-210.
[23] Karnes, J.H.; Cooper-DeHoff, R.M. Expert Rev. Cardiovasc. Ther. 2009, 7, 689-702.
[24] Elliott, W.J.; Meyer, P.M. Lancet. 2007, 369, 201-207.
[25] Kuzmanic, D.; Laganovic, M.; Dika, Z.; Kos, J.; Pecin, I. Lijec. Vjesn. 2006, 128, 336-341.
[26] Torp-Pedersen, C.; Metra, M.; Charlesworth, A.; Spark, P.; Lukas, M.A.; Poole-Wilson, P.A.; Swedberg, K.; Cleland, J.G.; Di Lenarda, A.; Remme, W.J.; Scherhag, A. Heart. 2007, 93, 968-973.
[27] Mcgill, J.B.; Bakris, G.L.; Fonseca, V.; Raskin, P.; Messerli, F.H.; Phillips, R.A.; Katholi, R.E.; Wright Jr., J.T.; Iyengar, M.; Anderson, K.M.; Lukas, M.A.; Dalal, M.R.; Bell, S.H. Diabetes Obes. Metab. 2007, 9, 408-417.
[28] Phillips, R.A.; Fonseca, V.; Katholi, R.E.; McGill, J.B.; Messerli, F.H.; Bell, D.S.; Raskin, P.; Wright, J.J.; Iyengar, M.; Anderson, K.M.; Lukas, M.A.; Bakris, G.L. J. Cardiometab. Syndr. 2008, 3, 211-217.
[29] Bell, D.S.; Bakris, G.L.; McGill, J.B. Diabetes Obes. Metab. 2009, 11, 234-238.

Analysis of antihypertensive regimens and their intended patients from
three hospitals in Beijing

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 14

Recommended Articles

Metrics

Comments

[1]	Yajie Liu, Yu Wang, Jiajia Li, Xiaoqing Xu, Xinru Li. Preparation and evaluation of doxorubicin-luminespib co-loaded multivesicular liposomes [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 736-742.
[2]	Dakuan Wang, Bo Peng, Mengmeng Qin, Minghui Li, Ge Song, Bing He, Hua Zhang, Wenbing Dai, Qiang Zhang, Xiangbao Meng, Huan Meng, Xueqing Wang. Integrated combination delivery of IDO inhibitor and paclitaxel for cancer treatment [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(1): 1-16.
[3]	Junsheng Xue, Siyuan Wang, Fangran Hao, Xiuyun Tian, Hong Su, Liang Yang, Qiming An, Chunyi Hao, Tianyan Zhou. Dopamine increases the anti-cancer efficacy of sunitinib in the treatment of pancreatic cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 689-700.
[4]	Wen Jiang, Chao Sun, Jue Wang, Qian Xin, Kailin Li, Tonggang Qi, Yun Luan. Protective effect of baicalin on experimental pulmonary arterial hypertension through inhibition of pulmonary vascular remodeling [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 719-728.
[5]	Xueling Wang, Yanqin Liang, Yuan Zhang, Bing He, Wenbing Dai, Hua Zhang, Xueqing Wang, Qiang Zhang. Combination therapy of cRGD-DOX self-assembled nanoparticles and bevacizumab for breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(9): 627-640.
[6]	Yin Ying, Yunfeng Sun, Hongchun Li, Bo Yang, Hui Wang, Qingmei Wu, Ping Huang. Effects and mechanisms of Artemisia argyi essential oil on monocrotaline-induced pulmonary hypertension in rats [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(3): 183-192.
[7]	Jiongxi Lei, Shuangchen Cong, Maoyuan Song, Wenxi Zhang, Guanghua Peng, Yuanyuan Zhang, Mengya Yin, Jiaxing Wang, Jiajia Li, Xinru Li. Preparation, characterization and evaluation of liposomal doxorubicin and harmine that show synergistic activity in vitro [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(9): 666-674.
[8]	Daiying Zhou, Li Ding, Xi Wang, Juan Ma, Wolin Huang, Susan Goodin, Xi Zheng. Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(11): 827-833.
[9]	Ting Sun, Xia Yuan, Wei Huang, Wei Guo, Zemei Ge, Runtao Li, Jingrong Cui . Effects and mechanism of proteasome inhibitor YSY01-A alone or in combination with cisplatin against A549 cells in vitro [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(9): 607-616.
[10]	Kong-Cai Zhu, Guo-Ying Cao^*, Xin Hu. Drug management of hypertension in hemodialysis patients [J]. , 2012, 21(3): 205-210.
[11]	Lin Jia, Bo Xu, Wei Guo, Ze-Mei Ge, Run-Tao Li, Jing-Rong Cui^* . Enhanced antitumor effect of TM208 in combination with 5-fluorouracil in H22 transplanted mice [J]. , 2011, 20(6): 615-626.
[12]	Wei Wei, Ji-Hua Fu^, Chang-Hai Su , Ying Shan, Yuan Wang, Shu-Jia Kong, Ji-Hui Zhao, Wan-Liang Lu^^*, Shu-Ming Wang, Li Wang. A continued study on the bisoprolol and isosorbide dinitrate transdermal patches: cardiovascular protection in spontaneously hypertensive rats [J]. , 2008, 17(3): 241-248.
[13]	Lu Hongdi, Tang Weixue, Zhou Jianfang. Analysis of the Combination Chemotherapy Effect In Vitro Utilizing the Median-effect Principle [J]. , 1999, 8(4): 229-232.
[14]	Zhen-Li Lin, Xiang-Lan Zhao. Pharmacokinetics and Pharmacodynamics of Nitrendipine [J]. , 1994, 3(2): 173-175.